<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00943527</url>
  </required_header>
  <id_info>
    <org_study_id>07-004850</org_study_id>
    <nct_id>NCT00943527</nct_id>
  </id_info>
  <brief_title>Hormonal Effects on Tc-99m Sestamibi Uptake in the Breast</brief_title>
  <official_title>Molecular Breast Imaging: Effect of Menstrual Cycle, Hormone Therapy, and Tamoxifen on Tc-99m Sestamibi Uptake in the Breast.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gamma Medica-Ideas</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to examine the effects of menstrual cycle, hormone therapy, and the use of
      tamoxifen on Tc-99m sestamibi uptake.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">110</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <description>Premenopausal Women who are not taking hormones or birth control. Ages 35-45 who have had a negative mammograph performed at the Mayo Clinic in Rochester within the last year.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <description>Women Initiating Hormone Therapy and have had a negative mammogram preformed at the Mayo Clinic Rochester within the last year.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <description>Women Initiating Tamoxifen who have had a negative mammogram preformed at the Mayo Clinic Rochester.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Community Sample
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Arm 1

        Inclusion Criteria:

          -  age 35-45

          -  have regular menstrual cycles as defined by having menstrual cycle length of 25-31
             days, with menstrual flow of 2-7 days, and no intermenstrual spotting or bleeding.

          -  have had a negative screening mammogram within one year prior to the MBI studies that
             is available for comparison.

        Exclusion Criteria:

          -  currently using any exogenous hormones (e.g., hormonal contraceptives, sex steroid
             hormones) or any estrogen receptor modulating drugs (e.g., tamoxifen, raloxifene) or
             any aromatase inhibitors

          -  have a personal history of any cancer, except non-melanomatous skin cancer

          -  unable to understand and sign the consent form

          -  pregnant or lactating

          -  physically unable to sit upright and still for 30 minutes

        Arm 2

        Inclusion Criteria:

          -  scheduled to begin one of the following regimens of HT:

          -  Any dosage of any formulation of systemic estrogen therapy in the setting of a prior
             hysterectomy

          -  Any dosage of continuous estrogen plus monthly, cyclic progesterone therapy where the
             progesterone therapy is the oral, micronized formulation

          -  had a negative screening mammogram within one year prior to the MBI studies that is
             available for comparison.

        Exclusion Criteria:

          -  have a personal history of any cancer, except non-melanomatous skin cancer

          -  unable to understand and sign the consent form

          -  pregnant or lactating

          -  physically unable to sit upright and still for 30 minutes

        Arm 3

        Inclusion Criteria:

          -  scheduled to begin treatment with tamoxifen Or are currently being treated with
             tamoxifen (for &gt; 1 month) and have had an MBI scan performed prior to its initiation

          -  have had or will have the following test performed at Mayo Clinic: #87966, Cytochrome
             P450 2D6 genotyping for Tamoxifen Hormonal Therapy

          -  have had a screening or diagnostic mammogram within one year of the MBI studies that
             is available for comparison.

        Exclusion Criteria:

          -  are using or have used any exogenous hormones (e.g., hormonal contraceptives, sex
             steroid hormones), any estrogen receptor modulating drugs other than tamoxifen, or any
             aromatase inhibitors from the time of 1 month prior to the first MBI until completion
             of the second MBI.

          -  have been treated or will be undergoing treatment with systemic chemotherapy or
             external radiation beam therapy to the breast from the time of 6 months prior to the
             first MBI until the completion of the second MBI.

          -  unable to understand and sign the consent form

          -  pregnant or lactating

          -  physically unable to sit upright and still for 30 minutes
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 20, 2009</study_first_submitted>
  <study_first_submitted_qc>July 21, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 22, 2009</study_first_posted>
  <last_update_submitted>January 23, 2012</last_update_submitted>
  <last_update_submitted_qc>January 23, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 25, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Deborah Rhodes</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Breast</keyword>
  <keyword>Menstrual Cycle</keyword>
  <keyword>Breast Cancer</keyword>
  <keyword>Hormone</keyword>
  <keyword>MBI</keyword>
  <keyword>Molecular Breast Imaging</keyword>
  <keyword>Breast Imaging</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
    <mesh_term>Tamoxifen</mesh_term>
    <mesh_term>Technetium Tc 99m Sestamibi</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

